SupermAb

SupermAb is a private Beijing-based biotech company developing cell-based immunotherapies for hematologic malignancies. Publicly visible pipeline information is limited, but the company appears focused on an antibody-conjugated natural killer cell approach known as AcNK, which uses a one-step enzymatic conjugation method to attach intact antibodies to NK cells without genetic modification. Its lead disclosed program, Sup-003 (AcNK-Sup003), targets CD20 and CD19 for relapsed or refractory B-cell non-Hodgkin lymphoma and is in an early clinical study in China. Corporate registry records indicate the company was founded in 2019 and remains active as a small private company. Overall, SupermAb looks like an early-stage oncology biotech centered on a targeted NK-cell platform rather than a broad commercial-stage therapeutics business.